NCT05275465View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

December 29, 2022

Study Completion Date

December 29, 2022

Conditions
Hepatitis B
Interventions
DRUG

HH-006

Different dose levels of HH-006

DRUG

Placebo

Different dose levels of placebo

Trial Locations (1)

4006

Q-Pharm Pty Ltd (Nucleus Network Pty Ltd), Brisbane

Sponsors

Lead Sponsor

Huahui Health
All Listed Sponsors
lead

Huahui Health

INDUSTRY

NCT05275465 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers | Biotech Hunter | Biotech Hunter